On November 22, 2017 TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, reported its participation in two upcoming investor conferences (Press release, TESARO, NOV 22, 2017, View Source [SID1234522235]). The two conferences are:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Citi 2017 Global Healthcare Conference at the Lotte New York Palace in New York, New York on Thursday, December 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will participate in an analyst-led moderated Q&A from 1:25 to 2:05 PM ET and in meetings with investors.

The Guggenheim Securities 5th Annual Boston Healthcare Conference at the Intercontinental in Boston, Massachusetts on Wednesday, December 13. Tim Pearson, Executive Vice President and CFO of TESARO, will participate in meetings with investors.
A live webcast of the analyst-led Q&A discussion at the Citi conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conference.